264 research outputs found

    On the exactness of the cavity method for Weighted b-Matchings on Arbitrary Graphs and its Relation to Linear Programs

    Full text link
    We consider the general problem of finding the minimum weight b-matching on arbitrary graphs. We prove that, whenever the linear programming relaxation of the problem has no fractional solutions, then the cavity or belief propagation equations converge to the correct solution both for synchronous and asynchronous updating

    An Approach for the Automated Generation of Engaging Dashboards

    Get PDF
    Organizations use Key Performance Indicators (KPIs) to monitor whether they attain their goals. To support organizations at tracking the performance of their business, software vendors offer dash boards to these organizations. For the development of the dashboards that will engage organizations and enable them to make informed deci sions, software vendors leverage dashboard design principles. However, the dashboard design principles available in the literature are expressed as natural language texts. Therefore, software vendors and organizations either do not use them or spend significant efforts to internalize and apply them literally in every engaging dashboard development process. We show that engaging dashboards for organizations can be automati cally generated by means of automatically visualized KPIs. In this con text, we present our novel approach for the automated generation of engaging dashboards for organizations. The approach employs the deci sion model for visualizing KPIs that is developed based on the dashboard design principles in the literature. We implemented our approach and evaluated its quality in a case study.Ministerio de Economía y Competitividad BELI (TIN2015-70560-R)Ministerio de Ciencia, Innovación y Universidades OPHELIA RTI2018-101204-B-C2

    Introduction to the special issue on codes on graphs and iterative algorithms

    Get PDF
    In the 50 years since Shannon determined the capacity of ergodic channels, the construction of capacity-approaching coding schemes has been the supreme goal of coding research. Finally today, we know of practical codes and decoding algorithms that can closely approach the channel capacity of some classical memoryless channels. It is a remarkable fact motivating this special issue that all known practical, capacity-approaching coding schemes are now understood to be codes defined on graphs, together with the associated iterative decoding algorithms

    The status of GEO 600

    Get PDF
    The GEO 600 laser interferometer with 600m armlength is part of a worldwide network of gravitational wave detectors. GEO 600 is unique in having advanced multiple pendulum suspensions with a monolithic last stage and in employing a signal recycled optical design. This paper describes the recent commissioning of the interferometer and its operation in signal recycled mode

    Effizienz und Wettbewerb im deutschen Bankensektor

    Full text link
    In diesem Papier geben wir einen Überblick über den Wettbewerb und die Effizienz im deutschen Bankensektor. Wir nehmen dabei die Entwicklung in den letzten 15 Jahren in den Blick. Frühere Studien für Deutschland weisen darauf hin, dass das deutsche Bankensystem durch monopolistische Konkurrenz und durch moderat hohe Kosteneffizienz gekennzeichnet ist. Zudem scheinen Wettbewerb und Effizienz positiv miteinander verbunden. Des weiteren bestanden deutliche Unterschiede zwischen großen und kleinen Banken. Kleine Banken bevorzugten mehr das traditionelle Bankgeschäft, geringere Risiken und haben eher auf regional segmentierten Märk ten agiert. Die gegenwärtige Krise könnte zu tieferen Änderungen im Bankensystem führen, mit möglichen Folgen für Wettbewerb und Effizienz.In this paper we review the main findings on competition and efficiency for the German banking sector. Our aim is to give a bird view of the evolution during the past 15 years. Previous studies on Germany point to a banking system dominated by monopolistic competition and moderate cost efficiency. Competition and efficiency seem to be positively related. Furthermore significant differences existed between small and large banks. The business model of small banks was often more traditional, they preferred less risk and they acted on more segmented regional markets. The current crisis may lead to deep changes of the banking system, potentially with consequences for competition and efficiency

    Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID)

    Get PDF
    ObjectiveThe objective of this article is to evaluate the safety and clinical outcome of rituximab treatment in systemic lupus erythematosus (SLE) patients refractory to standard of care therapy in a real-life setting in Germany. MethodsThe GRAID registry included patients with different autoimmune diseases who were given off-label treatment with rituximab. Data on safety and clinical response were collected retrospectively. In SLE patients, clinical parameters included tender and swollen joint counts, fatigue, myalgia, general wellbeing, Raynaud's and the SLEDAI index. Laboratory tests included dsDNA antibody titres, complement factors, hematologic parameters and proteinuria. Finally, the investigators rated their patients as non-, partial or complete responders based on clinical grounds. ResultsData from 85 SLE patients were collected, 69 female and 16 male, with a mean disease duration of 9.8 years. The mean follow-up period was 9.67.4 months, resulting in 66.8 patient years of observation. A complete response was reported in 37 patients (46.8%), partial response in 27 (34.2%), no response in 15 (19.0%). On average, major clinical as well as laboratory efficacy parameters improved substantially, with the SLEDAI decreasing significantly from 12.2 to 3.3 points. Concerning safety, one infusion reaction leading to discontinuation of treatment occurred. Infections were reported with a rate of 19.5 (including six severe infections) per 100 patient years. ConclusionWith the restrictions of a retrospective data collection, the results of this study confirm data of other registries, which suggest a favourable benefit-risk ratio of rituximab in patients with treatment-refractory SLE

    Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID)

    Get PDF
    ObjectiveThe objective of this article is to evaluate the safety and clinical outcome of rituximab treatment in systemic lupus erythematosus (SLE) patients refractory to standard of care therapy in a real-life setting in Germany. MethodsThe GRAID registry included patients with different autoimmune diseases who were given off-label treatment with rituximab. Data on safety and clinical response were collected retrospectively. In SLE patients, clinical parameters included tender and swollen joint counts, fatigue, myalgia, general wellbeing, Raynaud's and the SLEDAI index. Laboratory tests included dsDNA antibody titres, complement factors, hematologic parameters and proteinuria. Finally, the investigators rated their patients as non-, partial or complete responders based on clinical grounds. ResultsData from 85 SLE patients were collected, 69 female and 16 male, with a mean disease duration of 9.8 years. The mean follow-up period was 9.67.4 months, resulting in 66.8 patient years of observation. A complete response was reported in 37 patients (46.8%), partial response in 27 (34.2%), no response in 15 (19.0%). On average, major clinical as well as laboratory efficacy parameters improved substantially, with the SLEDAI decreasing significantly from 12.2 to 3.3 points. Concerning safety, one infusion reaction leading to discontinuation of treatment occurred. Infections were reported with a rate of 19.5 (including six severe infections) per 100 patient years. ConclusionWith the restrictions of a retrospective data collection, the results of this study confirm data of other registries, which suggest a favourable benefit-risk ratio of rituximab in patients with treatment-refractory SLE
    corecore